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Table 1









Italian (Calabria) 96 43 .448  .051
Spanisha 66 36 .545  .061
Sub-Saharan African:
Dendi 24 0 0
Bariba 26 2 .077  .052
Berba 32 3 .094  .051
Fon 96 8 .083  .028
Totalb 178 13 .073  .019
Asian:
Tharua 108 21 .194  .038
Chinesea 24 9 .375  .099
Indonesian 98 2 .020  .014
Amerindian:
Cayapaa 114 49 .430  .046
Mixed:
Ethiopian:
Amhara 54 4 .074  .033
Oromo 54 3 .055  .031
Totalb 108 7 .065  .024
African Ecuadoran:
Vichea 82 13 .183  .043
a Testable population, except for Calabrians (Italy), in Hardy-Wein-
berg equilibrium.
b Populations were pooled when compatibility was verified by a x2
test of heterogeneity.
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Heterogeneity in World Distribution of the
Thermolabile C677T Mutation in 5,10-
Methylenetetrahydrofolate Reductase
To the Editor:
Hyperhomocysteinemia now is recognized as an inde-
pendent risk factor for vascular disease (Clarke et al.
1991) and defects of the neural tube (Mills et al. 1995).
Genetic factors associated with hyperhomocysteinemia
are mutations in genes coding for enzymes involved in
the methionine-metabolism pathway, such as 5,10-
methylenetetrahydrofolate reductase (MTHFR) and cys-
tathionine b-synthase. Related environmental factors in-
clude low dietary intake or increased necessity of folate
or vitamins B6 and B12 (Fenton and Rosenberg 1995).
Recently, a common thermolabile MTHFR variant,
causing mild hyperhomocysteinemia in 30% of homo-
zygotes, was detected. The C677T single-nucleotide sub-
stitution was found to cause an amino acid change, from
alanine to valine (Frosst et al. 1995). The T677 allele is
distributed widely among populations showing a high
heterogeneity. The purpose of this study was to inves-
tigate the prevalence of the C677T MTHFR mutation
among the major ethnic groups. The high prevalence of
T677 homozygotes in preselected populations would re-
sult in the need for a higher dietary intake of folate, to
prevent in utero neural-tube defects and long-term vas-
cular damage (Molloy et al. 1997).
We studied a total of 437 unrelated, apparently
healthy subjects from the major ethnic groups, catego-
rized as follows: 81 Europeans (33 Spanish and 48 Ital-
ians); 89 sub-Saharan Africans (48 Fon, 13 Bariba, 16
Berba, and 12 Dendi); 115 Asians (49 Indonesians
[Java], 12 Chinese [Peking area], and 54 Tharus); 57
Amerindians (Cayapa population [Ecuador]); and some
mixed populations, namely, 54 Ethiopians (27 Amhara
and 27 Oromo) and 41 African Ecuadorans (Viche area).
All the subjects gave their informed consent for the study.
For information on the origins of the populations and
their geographical distribution, see the article by Pepe
et al. (1997) and the references cited therein. Genomic
DNA was extracted from peripheral blood–cell lym-
phocytes, was amplified by PCR, and was digested with
HinfI restriction enzyme. The bands were visualized by
ethidium-bromide staining, as described elsewhere (Ab-
bate et al. 1998). The mutation creates a new HinfI site,
which is absent in the wild-type allele. Pooled frequen-
cies were obtained as mean frequencies weighted for the
sample size, after the compatibility of the allele fre-
quencies was verified by the x2 test of heterogeneity.
Results are reported in table 1.
Our data show a marked heterogeneity in the prev-
alence of the T677 MTHFR allele among the major eth-
nic groups surveyed and, in some cases, evenwithin these
groups. The frequency among Europeans ranged from
.448 in Italian subjects to .545 in Spanish subjects,
whereas the prevalence among Asians and Africans was
within the ranges .041–.375 and 0–.094, respectively.
For the Amhara and the Oromo, the frequency of the
T677 allele was intermediate between that for the Eur-
opeans (∼.5) and the sub-Saharan Africans (!.1); this
also has been confirmed in previous studies on genetic
admixture in these populations (Scacchi et al. 1994; O.R.
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Figure 1 Allele frequencies of the T677 allele, with 1 standard
error. The populations, of which all are in Hardy-Weinberg equilib-
rium, were pooled when possible, after a heterogeneity test. Mixed
populations: a  Brazilians (Arruda et al. 1997); b  Colombians
(Camacho Vanegas et al. 1998); c  Amerindians, from Cayapa pop-
ulation (Ecuador) (this report); o  African Americans (McAndrew
et al. 1996; Austin et al. 1997); p  African Ecuadorans, from Viche
area (this report); and q  Ethiopians, from Amhara and Oromo (this
report). European and European-derived populations: d  Italians,
from Puglia (Grandone et al. 1997) and Campania (De Franchis et al.
1996); e southern Europeans, from Toscany (this report), Lombardia
(Cattaneo et al. 1997), and Spain (this report); f  central Europeans,
from France (Brulhart et al. 1997; Faure-Delanef et al. 1997), and
French Canadians (Frosst et al. 1995; Deloughery et al. 1996); g 
northern Europeans, from Great Britain (Narang et al. 1996; Papa-
petrou et al. 1996) and Ireland (Harmon et al. 1996; Kirke et al. 1996;
Molloy et al. 1997), Australians (Wilcken et al. 1996; van Bockxmeer
et al. 1997), and Americans (Deloughery et al. 1996; Ma et al. 1996;
McAndrew et al. 1996; Austin et al. 1997); and hDutch (Kluijtmans
et al. 1996). Asian populations: i Japanese (Izumi et al. 1996; Morita
et al. 1997) and Chinese (this report); l  Tharu (this report); and m
 Indonesians (this report). Western African populations: n Bariba,
Berba, Dendi, and Fon (this report). Data for the European and Eur-
opean-derived and the Asian populations are within hatched boxes in
order to show a possible north-south cline.
and G.P., unpublished data). Furthermore, whereas all
the sub-Saharan African populations had a low fre-
quency of T677, the Asian population displayed a re-
markable heterogeneity, with a very low value for In-
donesians (.041), a high value for the Chinese (.375),
and a value in between for the Tharus (.194). The Span-
ish population displayed a T677-allele frequency that is
even higher than that for the wild-type allele.
By pooling our frequency data on the T677-allele dis-
tribution among controls with those in the literature, we
confirmed the marked heterogeneity of the allele (fig. 1).
Therefore, this allele also is a good anthropological
marker for studies of genetic admixture. Among the hy-
brid populations, Colombians displayed a frequency rate
(.487) between that for the European and Amerindian
populations (fig. 1). It is noteworthy that in Europe, as
well as in Asia, the frequency of T677 seems to have an
increasing north-to-south cline and also displays micro-
heterogeneity in a single population (e.g., frequency in
the Italian population is .448–.556). Because the amount
of data available at present is small, this nonrandom
distribution cannot be assayed statistically.
It is well known that T677 may result in the need for
a higher folate intake, to obtain normal homocysteine
concentrations, and that homozygosity for T677, when
associated with a decreased intake of or an increased
requirement for folate, becomes pathogenic for vascular
disorders, especially as the individual ages (Rozen 1997),
and for particular conditions such as pregnancy, in
which preconceptional folate intake prevents 70% of
neural-tube defects. For these reasons and because of the
high heterogeneity of T677, more information needs to
be collected on the prevalence of homo- and heterozy-
gosity of the T677 mutation, by means of population-
based studies (Motulsky 1996). This information would
encourage specific preventive measures that could be
geared toward specific ethnic groups—for example, es-
pecially in large cosmopolitan cities, public-health ed-
ucation stressing the importance of optimal folic and B-
vitamin intake. This might have a positive effect on
prevention, clinical follow-up, and health care cost-ben-
efit ratios.
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NTBC and Alkaptonuria
To the Editor:
La Du (1998) sounds an appropriate note of caution in
posing the editorial question, “Are we ready to try to
cure alkaptonuria?” (i.e., with homogentisate 1,2-diox-
ygenase [HGO] gene-replacement therapy). He suggests
that localization of recombinant HGO to certain tissues
might lead to accumulation of reactive intermediates of
the tyrosine catabolic pathway. We would like to point
out an alternative therapy for alkaptonuria (La Du 1995;
MIM 203500) that obviates the problem of gene
localization.
The potential treatment consists of oral administra-
tion of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclo-
hexanedione, or NTBC, in combination with some di-
etary restriction of phenylalanine and tyrosine. NTBC
is a member of the triketone class of herbicides, which
cause plants to bleach. The triketone herbicides are
inhibitors of 4-hydroxyphenylpyruvate dioxygenase
(HPPD) (Schulz et al. 1993), the enzyme that produces
homogentisic acid (HA). Hence, NTBC should prevent
the production of HA, which is believed to cause the
signs and symptoms of alkaptonuria. NTBC binds to 4-
HPPD in a rapid and avid (inhibitory concentration
[IC]50  40 nM), but reversible, fashion and inhibits
both rat and human liver HPPD (Lindstedt et al. 1992;
Schulz et al. 1993).
NTBC is the first effective drug therapy for the fatal
hereditary disease tyrosinemia type I (Mitchell et al.
1997), which results from fumarylacetoacetate hydro-
lase deficiency. By reducing the supply of HA, NTBC
partially blocks the formation of fumarylacetoacetate
and thus lowers the concentration of oxidizing metab-
olites, which cause severe liver disease, hepatocellular
carcinoma, and renal tubular dysfunction in infants and
children with tyrosinemia type I (Mitchell et al. 1997).
Early studies have shown both biochemical and clinical
efficacy of NTBC (Lindstedt et al. 1992), and case re-
ports indicate improvement in peripheral neuropathy
(Gibbs et al. 1993) and renal disease (Pronicka et al.
1996). A murine model of tyrosinemia type I was treated
with NTBC and responded with increased longevity, im-
proved liver function, and partially normalized expres-
sion of hepatic mRNAs (Grompe et al. 1995). The only
side effect was liver steatosis.
In humans, NTBC appears to be well tolerated for
short and midterm administration and has been used at
least since 1992 (Lindstedt et al. 1992). Complica-
tions—namely, photophobia and the presence of corneal
crystals—have been observed in only one NTBC-treated
child. These findings disappeared within 48 h, when a
phenylalanine and tyrosine-restricted diet was intro-
duced, and did not recur subsequently (Mitchell et al.
1997). Theoretically, NTBC therapy could result in neu-
rological problems associated with tyrosinemia type II
(tyrosine aminotransferase deficiency) or with tyrosi-
nemia type III (4-HPPD deficiency) (Mitchell et al.
1997). Tyrosinemia type III has been diagnosed in only
two patients, both of whom were ascertained because
of neurological problems. One patient had mild ataxia,
and the other had seizures and cerebral atrophy. Since
these patients were evaluated because of their neurolog-
ical symptoms, a causal relationship between their bi-
ochemical abnormalities and neurological symptoms
cannot be determined. Patients treated with NTBC have
not been reported to experience neurological problems,
but dietary restriction of tyrosine and phenylalanine may
be important for the prevention of any neurological,
ophthalmological, and dermatological side effects of
high tyrosine levels.
Because NTBC side effects have been reported for only
a few patients, it may be prudent to await a more-de-
tailed analysis of the entire group of tyrosinemia type I
patients who have been treated with NTBC. However,
